A Study on Vonoprazan in the Real-world Clinical Practice in China

NCT ID: NCT04501627

Last Updated: 2023-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-24

Study Completion Date

2023-06-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety of Vonoprazan by assessing all adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs) in routine clinical settings in China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, non-interventional study in Chinese participants with RE who are receiving or will receive the standard treatment of vonoprazan. This study will assess the safety and effectiveness of vonoprazan in the real-world clinical practice.

The study will enroll approximately 3000 participants. The data will be collected through participants' medical records, self-reported questionnaires, and recorded information on symptom via diaries. All the participants will be assigned to a single observational cohort:

• Participants with RE

The multi-center trial will be conducted in China. The standard treatment will be of 4 weeks or it may reach up to 8 weeks if the dosing proves insufficient. All participants will be followed up for additional 2 weeks after the standard treatment. The overall duration of the study will be approximately 10 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophagitis Peptic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with RE

Participants diagnosed with RE who have received 20 milligram (mg) of vonoprazan in routine clinical practice, will be observed prospectively. Data will be collected from participants' medical records, self-reported questionnaires and recorded information on symptom via diaries.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must be undergoing treatment with Vonoprazan.
2. Must be at least 18 years old.
3. Provide signed informed consent indicating that they (or a legally acceptable representative) have been informed of all pertinent aspects of the study and are willing to participate.

Exclusion Criteria

1. Are currently enrolled in or plan to participate in any other clinical trials (that is interventional study).
2. Are contraindicated for Vonoprazan according to Product Package Insert.
3. With a known hepatic function impairment, including jaundice.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Takeda

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Hospital

Beijing, Beijing Municipality, China

Site Status

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Site Status

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, China

Site Status

Yongchuan Hospital of Chongqing Medical University

Yongchuan, Chongqing Municipality, China

Site Status

Lanzhou University Second Hospital

Lanzhou, Gansu, China

Site Status

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status

The Third Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status

Huazhong University of Science and Technology Union Shenzhen Hospital

Shenzhen, Guangdong, China

Site Status

Zhuhai People's Hospital

Zhuhai, Guangdong, China

Site Status

Heilongjiang Provincial Hospital (Nanshang)

Harbin, Heilongjiang, China

Site Status

Henan Provincial Peoples Hospital

Zhengzhou, Henan, China

Site Status

Union Hospital, Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, China

Site Status

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, China

Site Status

Changshu No.2 People's Hospital

Changshu, Jiangsu, China

Site Status

The Affiliated Drum Tower Hospital of Nanjing University

Nanjing, Jiangsu, China

Site Status

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Site Status

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Site Status

Nanjing First Hospital

Nanjing, Jiangsu, China

Site Status

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

Site Status

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

The First Hospital of Jilin University

Changchun, Jilin, China

Site Status

The First Hospital of China Medical University

Shenyang, Liaoning, China

Site Status

Qilu Hospital of Shandong University

Jinan, Shandong, China

Site Status

Shandong Provincial Hospital

Jinan, Shandong, China

Site Status

Qilu Hospital of Shandong University (Qingdao)

Qingdao, Shandong, China

Site Status

Weifang Peoples Hospital

Weifang, Shandong, China

Site Status

Yantai Affiliated Hospital of Binzhou Medical College

Yantai, Shandong, China

Site Status

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Site Status

Chengdu Third People's Hospital

Chengdu, Sichuan, China

Site Status

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status

General Hospital of Tianjin

Tianjin, Tianjin Municipality, China

Site Status

The Affiliated Hospital of Hangzhou Normal University

Hangzhou, Zhejiang, China

Site Status

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Site Status

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status

The Affiliated Hospital of Medical School of Ningbo University

Ningbo, Zhejiang, China

Site Status

Wenzhou Central Hospital

Wenzhou, Zhejiang, China

Site Status

The Second Affiliated Hospital of Wenzhou Medical College

Wenzhou, Zhejiang, China

Site Status

The Fourth Affiliated Hospital Zhejiang University School of Medicine

Yiwu, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Vonoprazan-4007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.